Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMA OTCMKTS:CLXPF NASDAQ:CYTK NASDAQ:KRYS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$17.13+2.4%$19.22$10.21▼$25.67$4.09B0.433.65 million shs568,816 shsCLXPFCybin$8.32-1.7%$7.83$0.49▼$3.38$1.24BN/A551,962 shs440,245 shsCYTKCytokinetics$37.05-0.5%$33.19$29.31▼$61.38$4.42B0.591.79 million shs176,867 shsKRYSKrystal Biotech$147.480.0%$136.57$122.80▼$219.34$4.26B0.67286,092 shs30,069 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%-9.62%-5.69%-14.82%+25.22%CLXPFCybin0.00%+8.90%+5.32%+13.20%+2,674.26%CYTKCytokinetics0.00%+0.59%+14.80%-1.85%-34.00%KRYSKrystal Biotech0.00%-0.46%+11.35%-8.91%-27.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics3.855 of 5 stars3.71.00.00.02.82.53.1CLXPFCybinN/AN/AN/AN/AN/AN/AN/AN/ACYTKCytokinetics4.0857 of 5 stars4.51.00.04.62.40.80.0KRYSKrystal Biotech4.5324 of 5 stars3.51.00.04.72.13.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.33Buy$27.6761.51% UpsideCLXPFCybin 0.00N/AN/AN/ACYTKCytokinetics 2.93Moderate Buy$70.9291.45% UpsideKRYSKrystal Biotech 3.00Buy$213.7544.94% UpsideCurrent Analyst Ratings BreakdownLatest CLXPF, ADMA, CYTK, and KRYS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/9/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$155.00 ➝ $176.006/24/2025KRYSKrystal BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$240.006/9/2025CYTKCytokineticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$71.00 ➝ $53.005/29/2025CYTKCytokineticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$103.00 ➝ $84.005/16/2025KRYSKrystal BiotechCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$215.00 ➝ $155.005/14/2025CYTKCytokineticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$72.00 ➝ $72.005/13/2025CYTKCytokineticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025ADMAADMA BiologicsRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.005/8/2025CYTKCytokineticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$55.00 ➝ $53.005/7/2025CYTKCytokineticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$82.00 ➝ $80.005/7/2025CYTKCytokineticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$86.00 ➝ $80.00(Data available from 7/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$426.45M9.59$0.55 per share30.91$1.48 per share11.57CLXPFCybin$680K1,818.14N/AN/A$0.44 per share18.91CYTKCytokinetics$18.47M239.54N/AN/A($1.15) per share-32.21KRYSKrystal Biotech$290.52M14.67$4.64 per share31.81$32.90 per share4.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics$197.67M$0.8520.1524.83N/A45.01%47.16%30.51%8/6/2025 (Estimated)CLXPFCybin-$24.42M-$0.24N/AN/AN/AN/AN/AN/AN/ACYTKCytokinetics-$589.53M-$5.29N/AN/AN/A-3,201.47%N/A-43.75%8/6/2025 (Estimated)KRYSKrystal Biotech$89.16M$4.1635.4514.63N/A37.17%14.64%13.28%8/4/2025 (Estimated)Latest CLXPF, ADMA, CYTK, and KRYS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ADMAADMA Biologics$0.14N/AN/AN/AN/AN/A8/14/2025Q2 2025CYTKCytokinetics-$1.32N/AN/AN/AN/AN/A8/4/2025Q2 2025KRYSKrystal Biotech$1.20N/AN/AN/A$95.42 millionN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 million5/6/2025Q1 2025CYTKCytokinetics-$1.41-$1.36+$0.05-$1.36$2.77 million$1.60 million5/6/2025Q1 2025KRYSKrystal Biotech$1.38$1.20-$0.18$1.20$98.66 million$88.18 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/ACLXPFCybinN/AN/AN/AN/AN/ACYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.226.583.36CLXPFCybinN/A13.5713.57CYTKCytokineticsN/A5.995.99KRYSKrystal BiotechN/A9.659.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%CLXPFCybin0.01%CYTKCytokineticsN/AKRYSKrystal Biotech86.29%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.70%CLXPFCybinN/ACYTKCytokinetics3.40%KRYSKrystal Biotech13.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million229.90 millionOptionableCLXPFCybin50148.60 millionN/ANot OptionableCYTKCytokinetics250119.43 million115.37 millionOptionableKRYSKrystal Biotech21028.90 million24.94 millionOptionableCLXPF, ADMA, CYTK, and KRYS HeadlinesRecent News About These CompaniesJennison Associates LLC Decreases Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)July 21 at 5:39 AM | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 20 at 5:19 AM | marketbeat.comC WorldWide Group Holding A S Lowers Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)July 18 at 10:27 AM | marketbeat.comKrystal Biotech, Inc. (NASDAQ:KRYS) Insider Suma Krishnan Sells 1,529 SharesJuly 17, 2025 | marketbeat.comInsider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 3,084 Shares of StockJuly 17, 2025 | marketbeat.comSuma Krishnan Sells 13,435 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) StockJuly 17, 2025 | marketbeat.comAlps Advisors Inc. Makes New $346,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)July 17, 2025 | marketbeat.comWilliam Blair Comments on Krystal Biotech FY2025 EarningsJuly 17, 2025 | americanbankingnews.comSegall Bryant & Hamill LLC Lowers Stock Holdings in Krystal Biotech, Inc. (NASDAQ:KRYS)July 16, 2025 | marketbeat.comAnalysts Set Expectations for Krystal Biotech Q2 EarningsJuly 16, 2025 | marketbeat.comM&T Bank Corp Purchases New Shares in Krystal Biotech, Inc. (NASDAQ:KRYS)July 16, 2025 | marketbeat.comWilliam Blair Lowers Earnings Estimates for Krystal BiotechJuly 15, 2025 | marketbeat.comKrystal Biotech doses first patient in EMERALD-1 phase 1/2 trial for neurotrophic keratitisJuly 14, 2025 | ophthalmologytimes.comOKrystal Biotech, Inc. (NASDAQ:KRYS) Holdings Cut by TimesSquare Capital Management LLCJuly 14, 2025 | marketbeat.comWilliam Blair Forecasts Lower Earnings for Krystal BiotechJuly 14, 2025 | marketbeat.comWilliam Blair Reduces Earnings Estimates for Krystal BiotechJuly 13, 2025 | americanbankingnews.comSuma Krishnan Sells 200 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) StockJuly 12, 2025 | insidertrades.comInsider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 200 Shares of StockJuly 11, 2025 | marketbeat.comInsider Selling: Krystal Biotech, Inc. (NASDAQ:KRYS) Insider Sells 6,927 Shares of StockJuly 11, 2025 | marketbeat.comCiti raises Krystal Biotech stock price target to $176 on KB801 trial ...July 11, 2025 | investing.comQ2 EPS Estimates for Krystal Biotech Decreased by AnalystJuly 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLXPF, ADMA, CYTK, and KRYS Company DescriptionsADMA Biologics NASDAQ:ADMA$17.13 +0.40 (+2.39%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Cybin OTCMKTS:CLXPF$8.32 -0.14 (-1.65%) As of 07/18/2025Cybin Inc., a life sciences company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Natures Journey. The Serenity Life segment engages in the research and development of pharmaceutical and nutraceutical psilocybin products. The Natures Journey segment focuses on non-psychedelic medical mushroom nutraceutical products. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.Cytokinetics NASDAQ:CYTK$37.04 -0.19 (-0.50%) As of 11:43 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$147.48 -0.02 (-0.01%) As of 11:42 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Q2 Could Be the Catalyst PayPal Investors Have Been Waiting For Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
